Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bio-Rad Laboratories

230.46
-1.2400-0.54%
Volume:648.33K
Turnover:148.83M
Market Cap:6.27B
PE:-2.99
High:231.99
Open:229.68
Low:227.53
Close:231.70
Loading ...

Bio - Restructuring Plan to Incur $45 Million to $50 Million in Costs

THOMSON REUTERS
·
14 Feb

Bio-Rad Laboratories' Q4 Adjusted Earnings, Revenue Fall

MT Newswires Live
·
14 Feb

Bio-Rad reports Q4 adjusted EPS $2.90, consensus $2.88

TIPRANKS
·
14 Feb

Bio-Rad sees FY25 currency neutral revenue growth 1.5%-3.5%

TIPRANKS
·
14 Feb

Bio-Rad to acquire Stilla Technologies

TIPRANKS
·
14 Feb

Bio-Rad Laboratories Q4 2024 Adj EPS $2.90 Beats $2.86 Estimate, Sales $667.50M Miss $679.30M Estimate

Benzinga
·
14 Feb

BRIEF-Bio-Rad Q4 Adjusted EPS USD 2.9 Vs. IBES Estimate USD 2.87

Reuters
·
14 Feb

Bio-Rad Q4 EBIT Margin 8.7%

THOMSON REUTERS
·
14 Feb

Bio-Rad Outlook FY Adjusted Revenue Growth 1.5-3.5%

THOMSON REUTERS
·
14 Feb

Bio-Rad Q4 Sales USD 667.5 Million VS. Ibes Estimate USD 679.3 Million

THOMSON REUTERS
·
14 Feb

Press Release: Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

Dow Jones
·
14 Feb

Bio-Rad Offers to Acquire Digital Pcr Developer Stilla Technologies

THOMSON REUTERS
·
14 Feb

Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

Business Wire
·
14 Feb

KALA BIO Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Feb

CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise

Zacks
·
12 Feb

KALA BIO Announces Chief Executive Officer Transition

GlobeNewswire
·
12 Feb

Oncocyte Prices $29 Million Stock Offerings

MT Newswires Live
·
11 Feb

OncoCyte Prices $29.1 Million Equity Offering

THOMSON REUTERS
·
10 Feb

OncoCyte Corp: Proceeds Expected to Fund Transplant Assay Through FDA Ivd Clearance and Commercial Launch

THOMSON REUTERS
·
10 Feb

Oncocyte Prices $29.1 Million Equity Offering

GlobeNewswire
·
10 Feb